The top 3 things you should know about CBG (Cannabigerol)


1 – What is CBG?


CBG was first identified in the 1960’s, at the same time that researchers began to identify other cannabinoids including CBD, THC, and CBC.  CBG is created by the cannabis plant when it is converted from the acidic version of CBG, called CBGA. It was later discovered that CBGA is the precursor to THCA, CBDA, CBCA, and other acidic cannabinoids, which in turn are converted into THC, CBD, CBC, and other cannabinoids.   

As a result of most CBGA being converted to other acidic cannabinoids, CBG is usually not found in high concentrations in cannabis plants.  To isolate CBG for inclusion in product development, cannabis plants are harvested prior to blossoming, before the CBGA is converted to other compounds

2 – What does CBG do?

CBG is a partial agonist of both CB1 and CB2 type cannabinoid receptors, meaning it interacts broadly with the endocannabinoid system.  A study in 2011 found that CBG is effective at increasing anandamide levels.  Anandamide is one of the body’s naturally produced cannabinoids which is responsible for modulating physiological functions including sleep, appetite, and memory.  Another study, conducted in 1975, found evidence working with rats that CBG is more effective than either CBD or THC at inhibiting update of GABA.  GABA (gamma aminobutyric acid) is a compound found in the brain that is important because of its role in regulating neuron activity. CBG was shown in a 2009 study to potentially block serotonin receptors. Additional research is needed to better understand the implications of these studies, but they are a promising foundation for future research.  

Most importantly, CBG is non-psychoactive, meaning it will not get you high.  In fact, like CBD, CBG is believed to counter the psychoactive effects of THC.  CBG may however interact with other cannabinoids, including THC, to alter the way they impact the body via an effect commonly referred to as the entourage effect.    


3 – Studied effects of CBG

As with most of the medical information available on Cannabis products, the benefits of CBG demand further research.  The studies that are available are pre-clinical, and are not sufficient for users to treat, diagnose, or cure any disorder or disease.  The safety and efficacy of CBG have not yet been proven in humans. Nevertheless, the medical information that is available appears to be promising:

  • A 2016 study  found that CBG may be effective at relieving symptoms of anxiety.

  • A 2008 study found that CBG may be a more potent analgesic than THC or CBD.

  • A 2011 study found that CBG may act similarly to some pharmaceutical non-steroidal anti-inflammatory drugs (NSAIDs) by acting as a COX-2 inhibitor.

  • A 2015 study found that CBG may be an effective neuroprotectant in animal models, specifically when tested in relation to Huntington’s Disease. 

  • A 2007 study found at CBG may be effective at interacting with cannabinoid receptors found in the skin, and may play a role in modulating symptoms of psoriasis.

While more research is needed before CBG can be considered for use as a treatment, the early evidence is encouraging.

Needed BlendsCopyright 2020 All Rights Reserved

All Products Contain .3% THC or Less These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.